Table 2 Infectious complications, which led to a medical consultation in the 12 months after aHSCT
Infection (causative agent if available) | Frequency | Occurrence after aHSCT, month | Treatment | Treatment duration, weeks |
|---|---|---|---|---|
CMV reactivation | 3/17 (17.6%); 3/6 of CMV IgG positive (50.0%) | 1 | Valganciclovir | 8 (prophylactic) |
1 | Valganciclovir | 8 (prophylactic) | ||
1 | Ganciclovir | 5 | ||
EBV reactivation | 1/17 (5.9%) | 2 | Rituximab 2 × 1 g | 2 |
Mycosis | 3/17 (17.6%) | |||
Nodular pneumonia | 1 | Voriconazole | 5 | |
Oral candidiasis | 9 | Nystatin | 12 (prophylactic) | |
Esophageal candidiasis | 6 | Fluconazole | 2 | |
Upper respiratory tract infection | 3/17 (17.6%) | 9 | Non | na |
1 | Azithromycin | 24 (prophylactic) | ||
10 | Amoxicillin/clavulanic acid | 1 | ||
Atypical pneumonia | 1/17 (5.6%) | 3 | Piperacillin/tazobactam + linezolid | 2 |
Pyelonephritis (Escherichia coli) | 1/17 (5.9%) | 11 | Ciprofloxacin | 1 |
Superinfected pancreatic pseudocyst (Streptococcus anginosus + Enterococcus faecalis and cloacae + Klebsiella pneumoniae) | 1/17 (5.9%) | 3 | Ceftriaxone + metronidazole, meropenem, ciprofloxacin; drainage, piperacillin/tazobactam, linezolid | 14 |
Lethal pneumonia with lactate acidosis | 1/17 (5.9%) | 9 | Piperacillin/tazobactam | 1 |